复锐医疗科技（01696）今日盘中大跌5.64%，延续昨日的跌势。盘中最低报5.74港元，成交额达1656.45万港元。该股昨日已重挫逾13%，连续两日的大跌引发市场关注。
消息面上，复锐医疗科技日前公布的2025年中期业绩不佳，成为股价下跌的主要原因。公司上半年收益为1.65亿美元，同比下降1.9%；母公司拥有人应占溢利为642.6万美元，同比大幅下降41.3%。业绩下滑主要归因于北美市场面临的挑战，包括高利率环境和消费疲软。此外，六月份因地区紧张局势导致运输受限，也略微延迟了部分收益的确认。
尽管公司整体业绩下滑，但其国际市场（不包括北美）仍实现了7.1%的增长。申万宏源分析认为，作为能量源医美器械的头部企业，复锐医疗科技依托直销网络强化了亚太地区的优势，注射填充业务有望打开第二增长曲线。虽然短期内北美市场表现拖累了整体业绩，但长期发展逻辑未变。分析师预计，随着达希斐产品的上市及联合治疗生态的放量，公司下半年业绩有望出现反弹。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.